Protect children in Africa from deadly meningitis

 
$19,701
$30,299
Raised
Remaining
Feb 13, 2012

Meningitis vaccine update for GlobalGiving

At the end of 2011, we celebrated the launch of MenAfriVac™ in a new group of countries and the successful completion of vaccine introduction in the original three.

As planned, in December 2011, Cameroon, Chad, and Nigeria became the fourth, fifth, and sixth countries in the African meningitis belt to introduce the new meningitis vaccine. All told, more than 20 million were protected: 15 million in Nigeria, 4 million in Cameroon, and 1.8 million in Chad.

Mali and Niger, both part of the historic launch of the vaccine in December 2010, successfully completed their phased approach to introduction. Both countries achieved coverage rates higher than 90 percent nationwide in the target age group (1 to 29 years old, the age of greatest risk). With help from Doctors Without Borders, Mali alone vaccinated more than 6 million people who did not receive the vaccine’s protection during the first round.

Results are highly promising: As 2011 came to an end, not a single case of group A meningococcal meningitis has been reported among the almost 20 million people who were vaccinated during the 2010 launch. All countries will continue to monitor and document the vaccine’s effectiveness.

What’s next? Cameroon, Chad, and Nigeria will continue their own phased introductions—hopefully, with equally impressive coverage rates—in 2012 and 2013. The three countries will conduct in-depth campaign evaluations in early 2012 to fine-tune their immunization strategies and prepare for the next phase of work.

Links:

Nov 21, 2011

Meningitis vaccine update

A new round of immunization campaigns will reach 36 million more people by the end of 2011 with protection against meningitis A. Cameroon, Chad, and Nigeria are the fourth, fifth, and sixth countries to introduce the revolutionary new MenAfriVac™ vaccine, providing a contiguous block of immunized populations across the heart of Africa’s meningitis belt. Their immunization campaigns in December will reach 22 million people. Additionally, Mali and Niger will vaccinate 14 million more people in the final phase of their immunization campaigns. By the end of 2011, nearly 65 million people are expected to have received the MenAfriVac™ vaccine.

Mali, Niger, and Burkina Faso were the first to introduce MenAfriVac™ in a massive immunization campaign in December 2010 to provide protection against devastating meningitis epidemics. While Burkina Faso launched the vaccine nationwide, immunizing close to 100 percent of its target population, Mali and Niger opted for a phased approach, beginning in districts at highest risk.

As the 2010-11 epidemic season came to a close in June, surveillance data compiled by the World Health Organization (WHO) show just four confirmed cases of meningitis A in Burkina Faso. Three of the four cases occurred in individuals from neighboring Togo who crossed the border for medical care, and the fourth case was a citizen of Burkina Faso who had not received the new vaccine. No confirmed cases were reported in Mali, while four cases were reported in Niger, all in unvaccinated individuals. While these initial data are extremely encouraging, continuing surveillance for cases of meningitis and robust systems for monitoring vaccination coverage will be crucial to confirm the impact of the vaccine as it is introduced across the meningitis belt.

Experts from PATH, WHO, and partner organizations have supported the ministries of health in Cameroon, Chad, and Nigeria in determining appropriate strategies for vaccine introduction to ensure sufficient vaccine supplies and availability of health care personnel, as well as adequate disease surveillance and vaccine safety monitoring systems.

Links:

Jul 14, 2011

Meningitis vaccine update

With the 2010-2011 epidemic season largely over, surveillance data compiled by the World Health Organization (WHO) show just four confirmed cases of meningitis A in Burkina Faso, the first country to introduce the vaccine nationwide. Three of the four cases occurred in individuals from neighboring Togo who crossed the border for medical care, and the fourth case was a citizen of Burkina Faso who had not received the new vaccine. No confirmed cases were reported in Mali, while four cases were reported in Niger, all in unvaccinated individuals. While these initial data are extremely encouraging, continuing surveillance for cases of meningitis and robust systems for monitoring vaccination coverage will be crucial to confirm the impact of the vaccine as it is introduced across the meningitis belt.

Six months ago, the three West African countries were the first to introduce a revolutionary new vaccine called MenAfriVac™, vaccinating nearly 20 million people in a massive immunization campaign. While Burkina Faso launched the vaccine nationwide, immunizing close to 100% of its target population, Mali and Niger opted for a phased approach, with campaigns in districts at highest risk conducted in late 2010 and the remainder to be conducted in late 2011.

Planning is now under way for a new round of immunization campaigns in 2011-2012. Campaigns will be finalized in Mali and Niger, and new campaigns will begin in Cameroon, Chad, and Nigeria, providing a contiguous block of immunized populations across the heart of the meningitis belt. Counting those vaccinated during the December 2010 campaigns, nearly 65 million people are expected to have received the MenAfriVac vaccine by the end of the year.

Experts from PATH, WHO, and partner organizations are supporting the ministries of health in Cameroon, Chad, and Nigeria in determining appropriate strategies for vaccine introduction to ensure sufficient vaccine supplies and availability of health care personnel, as well as adequate disease surveillance and vaccine safety monitoring systems.

About Project Reports

Project Reports on GlobalGiving are posted directly to globalgiving.org by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.

If you donate to this project or have donated to this project, you will get an e-mail when this project posts a report. You can also subscribe for reports via e-mail without donating or by subscribing to this project's RSS feed.

An anonymous donor will match all new monthly recurring donations, but only if 75% of donors upgrade to a recurring donation today.
Terms and conditions apply.
Make a monthly recurring donation on your credit card. You can cancel at any time.
Make a donation in honor or memory of:
What kind of card would you like to send?
How much would you like to donate?
gift Make this donation a gift, in honor of, or in memory of someone?

Organization

PATH

Seattle, WA, United States
http://www.path.org/

Project Leader

Donor Relations

Seattle, WA United States

Where is this project located?

Map of Protect children in Africa from deadly meningitis